Clinical Trials Logo

Painful Diabetic Neuropathy clinical trials

View clinical trials related to Painful Diabetic Neuropathy.

Filter by:

NCT ID: NCT03297294 Not yet recruiting - Clinical trials for Painful Diabetic Neuropathy

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

EMPADINE
Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).

NCT ID: NCT03228420 Recruiting - Clinical trials for Painful Diabetic Neuropathy

Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain

SENZA-PDN
Start date: July 20, 2017
Phase: N/A
Study type: Interventional

This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable, neuropathic lower limb pain due to diabetic neuropathy (Painful Diabetic Neuropathy or PDN). This study is a multi-center, prospective, randomized comparison of the two treatments.

NCT ID: NCT03202979 Recruiting - Clinical trials for Painful Diabetic Neuropathy

Trazodone in Painful Diabetic Neuropathy

Start date: May 16, 2017
Phase: Phase 2
Study type: Interventional

The aim of the study is to collect preliminary information on the effect of low doses of trazodone on pain intensity in patients with painful diabetic neuropathy and to evaluate the neuropathic pain symptoms, anxiety, sleep, quality of life, safety and tolerability.

NCT ID: NCT03066570 Recruiting - Clinical trials for Painful Diabetic Neuropathy

Graded Exposure in Patients With Painful Diabetic Neuropathy

PDN&GEXP
Start date: June 1, 2017
Phase: N/A
Study type: Interventional

Objective: To investigate the effects of a cognitive behavioural intervention targeting specific fears in patients with painful diabetic neuropathy, on physical activity and quality of life.

NCT ID: NCT02643251 Completed - Diabetic Neuropathy Clinical Trials

The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The study will include three (3) phases: Screening Phase, Treatment Phase, and Follow-up Phase. Subjects who qualify to participate will apply study drug to their feet three times daily and will record their daily pain scores using an interactive voice response system (IVRS) during the Treatment Phase for 12 weeks. Approximately 100 adult subjects will be randomized to receive Clonidine Gel or Clonidine Gel Comparator.

NCT ID: NCT02427464 Recruiting - Clinical trials for Diabetic Neuropathy, Painful

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Start date: April 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of bilateral intramuscular injections of VM202 versus placebo in the treatment of painful diabetic neuropathy. A total of 477 subjects will be randomized in a 2:1 ratio to one of two treatment groups: Treatment - VM202 - 318 subjects Control - Placebo (VM202 vehicle) - 159 subjects Randomization will be stratified by current use of gabapentin and/or pregabalin.

NCT ID: NCT02355158 Completed - Diabetes Clinical Trials

A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy

Start date: June 2014
Phase: Phase 2
Study type: Interventional

Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN. Subjects who have completed their 12-week participation in Study CLO-290 or Study CLO-310 are eligible to rollover into this study and receive active study drug in an open-label manner.

NCT ID: NCT02068027 Completed - Diabetic Neuropathy Clinical Trials

Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy

Start date: March 2014
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether clonidine gel is an effective treatment for reducing the pain associated with painful diabetic neuropathy.

NCT ID: NCT01556152 Withdrawn - Clinical trials for Painful Diabetic Neuropathy

A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)

Start date: n/a
Phase: Phase 2
Study type: Interventional

Diabetic peripheral neuropathy (DPN) represents a diffuse symmetric and length-dependent injury to peripheral nerves that has major implications on quality of life (QOL), morbidity, and costs from a public health perspective. Painful diabetic neuropathy affects 16% of patients with diabetes. Pharmacological agents used in the management of painful DPN mainly include tricyclic antidepressants, selective serotonin and norepinephrine reuptake inhibitors, opioids, and anti epileptic drugs. However, only two drugs (duloxetine and pregabalin) have been formally approved by the EMEA and the US FDA for the treatment of painful DPN. Generally, the available treatment options do not give total relief, are not effective in all patients, and only about one-third of patients may achieve more than 50% pain relief. Hence newer therapies are required for the treatment of DPN. This is randomized, double-blind, placebo-controlled, parallel group study. The study will include patients with type 1 or type 2 diabetes mellitus with history of pain attributed to DPN for least 6 months and no greater than 5 years. Patients will be recruited after providing written informed consent.

NCT ID: NCT01521598 Completed - Clinical trials for Painful Diabetic Neuropathy

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

Start date: January 2012
Phase: Phase 2
Study type: Interventional

Primary Objective: To evaluate the efficacy of SKL11197 for the treatment of diabetic peripheral neuropathy pain (DPN). Secondary Objective: To evaluate the safety and tolerability of SKL11197 in subjects with painful diabetic peripheral neuropathy. Primary Efficacy Endpoint: The primary efficacy outcome variable will be the time to exit from the double-blind phase because of inadequate pain relief.